SCCT Submits Evidence Review on CAC Scoring to BCBS
Earlier this month the SCCT, via the Advocacy Committee, submitted comments to Blue Cross Blue Shield on their Evidence Review of Computed Tomography to Detect Coronary Artery Calcium. The objective of this evidence review was to evaluate whether the use of CT CAC scoring reduces the risk of CAD among asymptomatic or symptomatic patients. Evidence Reviews such as this assess whether a medical test is clinically useful.
The Blue Cross Blue Shield Association (BCBSA) launched Evidence Street® in October 2015 to enable evidence reviews through a web-based platform. The evidence-based reviews or Evidence Street® Opinions published by Evidence Street® are leveraged by health care decision makers at BCBS Plans and external organizations to develop local medical and coverage policy.
As the SCCT comments emphasized, the available evidence suggests that when compared to the 10-year ASCVD risk score, use of CAC scoring among asymptomatic individuals at risk results in significant improvement in risk assessment, risk-reclassification, resource utilization, and utilization of preventive lifestyle and medical therapies. SCCT further highlighted the recent adoption of CAC testing in the 2018 Cholesterol Guidelines and the 2019 American College of Cardiology/ American Heart Association Prevention Guidelines.